Source: Vanguard [Nigeria]
“A promising new HIV prevention drug called lenacapavir has shown 100 percent efficacy in a clinical trial among adolescent girls and young women in South Africa and Uganda. The twice-yearly injection was found to be superior to daily Truvada, the current standard for pre-exposure prophylaxis (PrEP). This is according to Gilead Sciences, the developer of lenacapavir. In a release signed by Kay Marshall, Senior Communications Advisor for AVAC, the organization welcomes the groundbreaking results of the PURPOSE 1 study which enrolled over 5,300 cisgender adolescent girls and young women ages between the age of 16 and 26 in South Africa and Uganda” (06/22/24)
https://www.vanguardngr.com/2024/06/groundbreaking-hiv-prevention-drug-shows-100-efficacy/